Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The use of oncolytic viruses for treatment of cancer marks a significant alteration in the battle between host and virus. Viruses are confronted by cellular innate immune responses and contain an armamentarium of immunomodulatory proteins that suppress innate immunity. Tumorigenesis can result in impairment of innate immune responses. Viruses engineered to be vulnerable to normal responses may mediate tumor-specific killing with minimal off-target toxicity. OBJECTIVE: To examine the mechanisms by which mammalian cells respond to viral infections in normal versus cancer cells and how viruses overcome these responses and to illustrate how this knowledge is used to develop physiologically targeted oncolytic viruses. METHODS: Literature describing studies investigating innate responses to virus infections, cancer-specific molecular defects, immunosuppressive viral products and design of oncolytic viruses is extensively reviewed, and pertinent concepts are distilled and developed. RESULTS/CONCLUSION: Innate responses to viral infections are complex involving i) viral detection; ii) induction of interferon and other cytokines; and iii) establishment of an antiviral state. Oncolytic viruses are engineered to be susceptible to antiviral responses in normal cells. Cancers can be partially vulnerable to these viruses because they have defective antiviral responses but the antitumor potency of physiologically targeted viruses may be significantly diminished.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888 · cited 1×
“RIG-I and MDA5 are critical in viral detection as indicated by the susceptibility of knockout mice to viral infection [16].”
BackgroundCell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 1×
“Clearly these activities are counter to the survival strategy of cancer cells and are therefore frequently compromised through mutation or underexpression [45,46].”
BackgroundSTING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
Ishikawa, H., & Barber, G. N. (2008) · Nature · doi:10.1038/nature07317 · Cited by 3,576 · cited 1×
“Interestingly, a protein localized to the translocon complex at the endoplasmic reticulum (ER), STING, has recently been suggested to play a role in DNA-dependent IPS-1 signaling, facilitating both RIG-I and DNA-induced IRF3 activation [22].”
BackgroundThe Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor
Schindler, C., Shuai, K., Prezioso, V. R., & Darnell, J. E. (1992) · Science · doi:10.1126/science.1496401 · Cited by 899 · cited 1×
“IFN binds IFN receptors at the cell surface and signals through STAT proteins, specifically STAT-1 and STAT-2 [27].”
BackgroundTakaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · cited 8×
“Thus IFN may preferentially induce quiescence (translational shutdown) in uninfected cells, but apoptosis in infected cells. p53 expression is critical in mediating the pro-apoptotic actions of Type I IFNs [32] but also promotes increased expression of Fas, TRAIL and pro-apoptotic BCl-2 family proteins [33].”
BackgroundInfluentialPKR; a sentinel kinase for cellular stress
Williams, B. R. (1999) · Oncogene · doi:10.1038/sj.onc.1203127 · Cited by 820 · cited 1×
“PKR recognizes and binds dsRNA viral intermediates via a dsRNA-binding motif (dsRBM), dimerizes upon activation to form a functional kinase domain and then phosphorylates eIF2α to inhibit translation of viral and cellular proteins [30].”
BackgroundCellular targets for transformation by the adenovirus E1A proteins
Whyte, P., Williamson, N. M., & Harlow, E. (1989) · Cell · doi:10.1016/0092-8674(89)90984-7 · Cited by 729
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402 · cited 1×
“Significant progress with VV oncolytics has taken place in an industrial setting with a conscious effort made to incorporate multiple mechanisms of action [56].”
Background
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationOncolytic viruses as therapeutic cancer vaccines
Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., & Guo, Z. S. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-103 · Cited by 324
The Sodium/Iodide symporter (NIS): Molecular physiology and preclinical and clinical applications
Ravera, S., Reyna-Neyra, A., Ferrandino, G., Amzel, L. M., & Carrasco, N. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034125 · Cited by 298
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
Guo, Z. S., Liu, Z., & Bartlett, D. L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00074 · Cited by 284
Leonova, K. I., Brodsky, L., Lipchick, B., Pal, M., Novototskaya, L., Chenchik, A. A., Sen, G. C., Komarova, E. A., & Gudkov, A. V. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216922110 · Cited by 261
Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses
Miller, A., Nace, R., Ayala-Breton C, C., Steele, M., Bailey, K., Peng, K. W., & Russell, S. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.219 · Cited by 38
Self-citation
Metadata
- Authors
- Naik, S., & Russell, S. J.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2009-07-28
- Volume
- 9
- Issue
- 9
- Pages
- 1163-1176
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W1970060539
- Cited by
- 110
- References
- 12
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.